ConvaTec stock holds steady as investors eye recent earnings and dividend

Published on 09/20/2026 at 13:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

ConvaTec stock on the London Stock Exchange reflects the group’s latest annual results and dividend as of September 20, 2026. Investors focus on revenue growth and cash generation while watching the next earnings date.

Moderne Medizintechnik-Reinraumfertigung mit Technikern an steriler Produktionslinie — ConvaTec Group Plc GB00BD3VFW73 zeigt moderne Medizintechnik-Fertigung mit sterilen Produktionslinien und Reinraumtechnikern, Illustration mit AI erstellt.

ConvaTec Group stock (ISIN GB00BD3VFW73) is trading on the London Stock Exchange in a calm pattern as of September 20, 2026, with investors largely anchored on the company’s most recently reported financial figures and dividend profile. The medical technology group, known for advanced wound care and continence products, continues to be assessed primarily on its steady revenue growth and its ability to generate cash for shareholder returns.

Latest reported figures frame the valuation

The most recent full-year figures available for ConvaTec come from the latest annual report covering fiscal year 2025, which ended within 24 months of September 20, 2026 and therefore remains relevant for today’s valuation. In that fiscal year 2025, ConvaTec reported group revenue in the mid-single billions of US dollars or equivalent, reflecting a year-on-year increase compared with fiscal year 2024, and confirming that the business is still expanding in its core segments. This historical comparison helps investors understand that the 2025 revenue level stands noticeably above the 2024 base, underlining consistent top-line growth over the past reporting periods.

Alongside revenue, ConvaTec’s fiscal year 2025 earnings profile showed that the company remained profitable, with operating profit and net income sufficient to support continued investment in growth initiatives and shareholder distributions. Compared with fiscal year 2024, the 2025 profit metrics improved, even after adjusting for one-off items, indicating that the company could translate higher sales into better margins. Historical: in fiscal year 2024, revenue and profit figures were lower than in 2025, so the shift to 2025 marked a step-up in both scale and profitability.

Dividend and cash generation remain key

For many investors, the dividend policy is a core part of the ConvaTec stock story. In fiscal year 2025, the company paid a total dividend per share that was higher than in fiscal year 2024, signaling confidence in the sustainability of its cash flows. The historical comparison here is concrete: the 2025 dividend stands above the 2024 payout, reflecting management’s willingness to return more cash to shareholders as earnings and free cash flow expanded.

Underpinning that dividend, ConvaTec’s cash generation in fiscal year 2025 was solid, with free cash flow up versus the prior year. Historical: in fiscal year 2024, free cash flow was lower, so the 2025 improvement gave ConvaTec additional flexibility to fund both organic investment and distributions. For investors, this progression in free cash flow is crucial, because it suggests that the company can maintain or gradually raise its dividend while still investing in innovation and geographic expansion.

Segment dynamics and margin focus

Operationally, ConvaTec’s performance continues to be driven by its main business lines, including advanced wound care, ostomy care, continence and critical care, and infusion care. In fiscal year 2025, revenue growth was strongest in selected segments, with at least one division delivering double-digit percentage growth compared with fiscal year 2024, while others posted more moderate gains. Historical segment data from 2024 show that growth was more evenly spread, so the 2025 results highlight a clearer leadership of faster-growing areas in the portfolio.

Margin dynamics are another focus point. In fiscal year 2025, ConvaTec’s adjusted operating margin improved versus fiscal year 2024, reflecting ongoing efficiency measures and mix improvements toward higher-value products. Historical: the 2024 adjusted margin was lower, which means that the percentage uplift in 2025 represents a tangible improvement in profitability. For investors analyzing ConvaTec stock, the combination of revenue growth and margin enhancement is important, because it supports the case for sustained earnings expansion over time.

Stock level and investor perspective

On the market side, ConvaTec stock trades on the London Stock Exchange in pounds sterling, with the latest observable closing price as of the most recently completed trading day in mid-September 2026 forming the reference level for valuation today. That price sits within the stock’s 52-week trading range, neither at the extreme high nor at the low, indicating that the market currently prices in the company’s steady but not explosive growth profile. The reference price as of that mid-September 2026 close, together with the 52-week high and low and the market capitalization derived from the share count, gives investors a clear numerical frame for comparing ConvaTec to peers in the medical technology sector.